Subretinal Injection: A Review on the Novel Route of Therapeutic Delivery for Vitreoretinal Diseases
The DOI matches its Crossref record; 108 of the 108 references it cites were found in a registry or an index.
Abstract
Compared to intravitreal injection, subretinal injection has more direct effects on the targeting cells in the subretinal space, which provides a new therapeutic method for vitreoretinal diseases, especially when gene therapy and/or cell therapy is involved. To date, subretinal delivery has been widely applied by scientists and clinicians as a more precise and efficient route of ocular drug delivery for gene therapies and cell therapies including stem cells in many degenerative vitreoretinal diseases, such as retinitis pigmentosa, age-related macular degeneration, and Leber's congenital amaurosis. However, clinicians should be aware of adverse events and possible complications when performing subretinal delivery. In the present review, the subretinal injection used in vitreoretinal diseases for basic research and clinical trials is summarized and described. Different methods of subretinal delivery, as well as its benefits and challenges, are also briefly introduced.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Subretinal drug is administered between the retinal photoreceptor cells and the RPE layer, requires less vector than intravitreal injections to achieve a therapeutic effect on the retina.127”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [127]
In the citing paper
“Despite these advantages, intravitreal injections also carry risks of adverse reactions, including inflammation, endophthalmitis, increased intraocular pressure, retinal detachment, hemorrhage, and cataracts, and due to the repeated use of these injections in various treatments, patient compliance can become an issue.119,127,129”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [127]
In the citing paper
“However, this route of administration can further damage an already damaged retina, leading to retinal or RPE detachment from underlying layers, hemorrhage, and changes in retinal pigmentation.35,127,128”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [127]
In the citing paper
“Most gene therapy viral vectors given intravitreally, fail to adequately transduce photoreceptors and RPE, due to the inner limiting membrane that divides the vitreous from the retina.1,15,119,127”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [127]
Citations
Cites
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
Heier, J. S., Brown, D. M., Chong, V., Korobelnik, J.-F., Kaiser, P. K., Nguyen, Q. D., Kirchhof, B., Ho, A., Ogura, Y., Yancopoulos, G. D., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.09.006 · Cited by 2,485
Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Embryonic stem cell trials for macular degeneration: a preliminary report
Schwartz, S. D., Hubschman, J.-P., Heilwell, G., Franco-Cardenas, V., Pan, C. K., Ostrick, R. M., Mickunas, E., Gay, R., Klimanskaya, I., & Lanza, R. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60028-2 · Cited by 1,409
Gaudana, R., Ananthula, H. K., Parenky, A., & Mitra, A. K. (2010) · The AAPS Journal · doi:10.1208/s12248-010-9183-3 · Cited by 1,406
Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics
Kay, M. A., Glorioso, J. C., & Naldini, L. (2001) · Nature Medicine · doi:10.1038/83324 · Cited by 1,342
Ghasemi Falavarjani, K., & Nguyen, Q. D. (2013) · Eye · doi:10.1038/eye.2013.107 · Cited by 982
Hauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.107 · Cited by 954
Ocular drug delivery systems: An overview
Patel, A. (2013) · World Journal of Pharmacology · doi:10.5497/wjp.v2.i2.47 · Cited by 890
Maguire, A. M., High, K. A., Auricchio, A., Wright, J. F., Pierce, E. A., Testa, F., Mingozzi, F., Bennicelli, J. L., Ying, G.-S., Rossi, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61836-5 · Cited by 865
Cited by
Therapeutic in vivo delivery of gene editing agents
Raguram, A., Banskota, S., & Liu, D. R. (2022) · Cell · doi:10.1016/j.cell.2022.03.045 · Cited by 522
“, via subretinal injection) can circumvent biological barriers and enable access to certain important cell populations (Bottros and Christo, 2014; Peng et al., 2017).”
BackgroundVarela-Fernández, R., Díaz-Tomé, V., Luaces-Rodríguez, A., Conde-Penedo, A., García-Otero, X., Luzardo-Álvarez, A., Fernández-Ferreiro, A., & Otero-Espinar, F. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12030269 · Cited by 354
“Subretinal delivery can also be used for stem cell transplantation in ocular degenerative diseases, which was reported in vivo studies and aimed at clinical applications [224].”
BackgroundMethodInfluentialMammalian Near-Infrared Image Vision through Injectable and Self-Powered Retinal Nanoantennae
Ma, Y., Bao, J., Zhang, Y., Li, Z., Zhou, X., Wan, C., Huang, L., Zhao, Y., Han, G., & Xue, T. (2019) · Cell · doi:10.1016/j.cell.2019.01.038 · Cited by 292
“As sub-retinal injections are a commonly used ophthalmological practice in animals and humans (Hauswirth et al., 2008; Peng et al., 2017), our pbUCNPs were dissolved in PBS and then injected into the sub-retinal space in the eyes of mice.”
The effects of PEGylation on LNP based mRNA delivery to the eye
Ryals, R. C., Patel, S., Acosta, C., McKinney, M., Pennesi, M. E., & Sahay, G. (2020) · PLOS ONE · doi:10.1371/journal.pone.0241006 · Cited by 194
“Specific to treating the retina, clinicians and scientists are in much debate over the visual impact of detaching the fovea and/or a fragile degenerating retina during a subretinal injection [6].”
BackgroundGasparini, S. J., Llonch, S., Borsch, O., & Ader, M. (2019) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.11.001 · Cited by 186
Jacob, S., Nair, A. B., Shah, J., Gupta, S., Boddu, S. H. S., Sreeharsha, N., Joseph, A., Shinu, P., & Morsy, M. A. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14030533 · Cited by 163
“ocular pressure, and post-operative development of choroidal neovascularization [21].”
BackgroundIntravitreal hydrogels for sustained release of therapeutic proteins
Ilochonwu, B. C., Urtti, A. O., Hennink, W. E., & Vermonden, T. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.07.031 · Cited by 164
Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions
Drag, S., Dotiwala, F., & Upadhyay, A. K. (2023) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.64.7.39 · Cited by 145
Retinitis Pigmentosa: Current Clinical Management and Emerging Therapies
Nguyen, X., Moekotte, L., Plomp, A. S., Bergen, A. A. B., van Genderen, M. M., & Boon, C. J. F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087481 · Cited by 150
“While subretinal delivery has a more direct effect on photoreceptor cells, it provides treatment only for a limited region of the retina, thus requiring multiple or larger treatment zones for better outcomes [298].”
BackgroundGene therapy beyond luxturna: a new horizon of the treatment for inherited retinal disease
Prado, D. A., Acosta-Acero, M., & Maldonado, R. S. (2020) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000660 · Cited by 114
Review of gene therapies for age-related macular degeneration
Khanani, A. M., Thomas, M. J., Aziz, A. A., Weng, C. Y., Danzig, C. J., Yiu, G., Kiss, S., Waheed, N. K., & Kaiser, P. K. (2022) · Eye · doi:10.1038/s41433-021-01842-1 · Cited by 119
“injection, two routes of delivery have been utilized: (1) A transscleral route passing through the choroid without penetrating the retina and without the need for vitrectomy; (2) A transvitreal route passing through the pars plana, vitreous, and retina into the subretinal space without penetrating the choroid [47].”
BackgroundMethodSubretinal injection techniques for retinal disease: A review
Irigoyen, C., Amenabar Alonso, A., Sanchez-Molina, J., Rodríguez-Hidalgo, M., Lara-López, A., & Ruiz-Ederra, J. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11164717 · Cited by 106
“effec ive in the delivery of drug into the SRS [15].”
BackgroundMethodInfluentialNanomedicine and drug delivery to the retina: current status and implications for gene therapy
Tawfik, M., Chen, F., Goldberg, J. L., & Sabel, B. A. (2022) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-022-02287-3 · Cited by 101
“Therefore, subretinal delivery may result in suboptimal therapeutic benefits for diseases that benefit most from diffuse transduction of peripheral retinal signals, such as retinitis pigmentosa (Peng et al. 2017; Simunovic et al. 2017; Ghazi et al. 2016).”
BackgroundFundamentals, challenges, and nanomedicine‐based solutions for ocular diseases
Srinivasarao, D. A., Lohiya, G., & Katti, D. S. (2018) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1548 · Cited by 95
Habot‐Wilner, Z., Noronha, G., & Wykoff, C. C. (2019) · Acta Ophthalmologica · doi:10.1111/aos.14042 · Cited by 83
“As a strategy for targeted delivery, subretinal injection of genetic material has the advantage of being available directly to the photoreceptors and RPE cells, providing potential for access to these cells for the treatment of disorders due to mutations in photoreceptor and/or RPE genes (Peng et al. 2017).”
BackgroundTargeting Ocular Drug Delivery: An Examination of Local Anatomy and Current Approaches
Dosmar, E., Walsh, J., Doyel, M., Bussett, K., Oladipupo, A., Amer, S., & Goebel, K. (2022) · Bioengineering · doi:10.3390/bioengineering9010041 · Cited by 91
Tuwahatu, C. A., Yeung, C. C., Lam, Y. W., & Roy, V. A. L. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.08.023 · Cited by 78
Devoldere, J., Peynshaert, K., Dewitte, H., Vanhove, C., De Groef, L., Moons, L., Özcan, S. Y., Dalkara, D., De Smedt, S. C., & Remaut, K. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.06.042 · Cited by 66
Adeno-Associated Viral Gene Therapy for Inherited Retinal Disease
Ong, T., Pennesi, M. E., Birch, D. G., Lam, B. L., & Tsang, S. H. (2019) · Pharmaceutical Research · doi:10.1007/s11095-018-2564-5 · Cited by 78
The future of retinal gene therapy: evolving from subretinal to intravitreal vector delivery
Ross, M., & Ofri, R. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.306063 · Cited by 67
“First, an SR injection inevitably detaches the photoreceptor layer from the supporting RPE layer, thereby compromising the photoreceptors’ function and survival, let alone in a degenerated retina (Jacobson et al., 2006; Peng et al., 2017).”
BackgroundLeroy, B. P., Birch, D. G., Duncan, J. L., Lam, B. L., Koenekoop, R. K., Porto, F. B. O., Russell, S. R., & Girach, A. (2021) · Retina · doi:10.1097/iae.0000000000003133 · Cited by 71
Zhang, K. Y., & Johnson, T. V. (2021) · Experimental Eye Research · doi:10.1016/j.exer.2021.108545 · Cited by 73
Wan, C.-R., Muya, L. W., Kansara, V. S., & Ciulla, T. A. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13020288 · Cited by 69
“The standard for ocular gene therapy administration is subretinal injection, a highlyspecialized surgical procedure, which is generally performed at selected Centers of Excellence, given the potential complications of pars plana vitrectomy associated procedures such as retinotomy [78,79].”
Poorten, E. V., Riviere, C. N., Abbott, J. J., Bergeles, C., Nasseri, M. A., Kang, J. U., Sznitman, R., Faridpooya, K., & Iordachita, I. I. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814245-5.00036-0 · Cited by 78
Progress on ocular siRNA gene‐silencing therapy and drug delivery systems
Jiang, J., Zhang, X., Tang, Y., Li, S., & Chen, J. (2021) · Fundamental & Clinical Pharmacology · doi:10.1111/fcp.12561 · Cited by 54
Mashal, M., Attia, N., Martínez-Navarrete, G., Soto-Sánchez, C., Fernández, E., Grijalvo, S., Eritja, R., Puras, G., & Pedraz, J. L. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.05.010 · Cited by 58
Microsurgery Robots: Applications, Design, and Development
Wang, T., Li, H., Pu, T., & Yang, L. (2023) · Sensors · doi:10.3390/s23208503 · Cited by 62
“Subretinal injection is an intravitreal drug delivery method increasingly used in oph-thalmology for the treatment of common retinal diseases, such as gene and stem cell therapy, sub-macular hemorrhage, and age-related macular degeneration (AMD) [25,26].”
BackgroundMethodPrecision genome editing in the eye
Suh, S., Choi, E. H., Raguram, A., Liu, D. R., & Palczewski, K. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2210104119 · Cited by 54
Subretinal therapy: technological solutions to surgical and immunological challenges
Ladha, R., Caspers, L. E., Willermain, F., & de Smet, M. D. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.846782 · Cited by 54
“Three surgical approaches are currently proposed to reach the retina: direct intravitreal injection which fills the core of the eye and exposes all intraocular surfaces in contact with the vitreous to the vectors or cells, or by injecting the suspension under the sensory retina either by a transvitreal route or reachi…”
BackgroundHakim, A. M., Guido, B., Narsineni, L., Chen, D.-W., & Földvári, M. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114781 · Cited by 56
Interleukin-17: The Role for Pathological Angiogenesis in Ocular Neovascular Diseases
Li, Y., & Zhou, Y. (2019) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.247.87 · Cited by 55
“As a novel gene editing technique which has been applied in the eye (Huang et al. 2017), the CRISPR/Cas9 system could also be used to deplete IL-17 in the ocular disease model in both biological study and future clinical applications (Peng et al. 2017a).”
BackgroundMethodSelf-citationThe structure and function of the human choroid
Zhang, W., Kaser-Eichberger, A., Fan, W., Platzl, C., Schroedl, F., & Heindl, L. M. (2024) · Annals of Anatomy - Anatomischer Anzeiger · doi:10.1016/j.aanat.2024.152239 · Cited by 58
Zeng, S., Chen, Y., Zhou, F., Zhang, T., Fan, X., Chrzanowski, W., Gillies, M. C., & Zhu, L. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114965 · Cited by 53
Rowe, L. W., & Ciulla, T. A. (2024) · Genes · doi:10.3390/genes15060720 · Cited by 53
“These complications can include macular holes, potential photoreceptor damage due to bleb creation, retinotomy with hemorrhage and fibrosis, retinal tears and detachment, and cataracts (Figure 1) [1].”
BackgroundStem cell therapy for inherited retinal diseases: a systematic review and meta-analysis
Chen, X., Xu, N., Li, J., Zhao, M., & Huang, L. (2023) · Stem Cell Research & Therapy · doi:10.1186/s13287-023-03526-x · Cited by 46
“Although this method involves a pars plana vitrectomy which may lead RD and vitrectomy-associated complications, the successful use of hESC-RPE in subretinal space has shown its relative safety when carefully using the right techniques [53].”
MethodScruggs, B. A., Jiao, C., Cranston, C. M., Kaalberg, E., Wang, K., Russell, S. R., Wiley, L. A., Mullins, R. F., Stone, E. M., Tucker, B. A., et al. (2019) · Stem Cells Translational Medicine · doi:10.1002/sctm.18-0210 · Cited by 40
Tissue Engineering Strategies for Retina Regeneration
Nair, D. S. R., Seiler, M. J., Patel, K. H., Thomas, V., Camarillo, J. C. M., Humayun, M. S., & Thomas, B. B. (2021) · Applied Sciences · doi:10.3390/app11052154 · Cited by 48
“Previously, subretinal delivery of cells through bolus injection has laid the groundwork and provided the "proof of concept" that healthy donor stem and progenitor cells can be transplanted into a diseased retina to contribute to visual functional recovery [70,71].”
BackgroundOcular barriers as a double-edged sword: preventing and facilitating drug delivery to the retina
Wang, L., & Zhang, H. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-022-01231-5 · Cited by 44
“As the two neighboring tissues are easily separated under moderate external forces, a relatively large volume of materials can be placed into the space for the treatment of hereditary or degenerative retinal disorders [94].”
BackgroundDmour, I. M. (2024) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2024.122486 · Cited by 43
Vasconcelos, H. M., Lujan, B. J., Pennesi, M. E., Yang, P., & Lauer, A. K. (2020) · International Journal of Retina and Vitreous · doi:10.1186/s40942-020-00216-1 · Cited by 39
Salman, A., Kantor, A., McClements, M. E., Marfany, G., Trigueros, S., & MacLaren, R. E. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091842 · Cited by 37
Genome Editing, A Superior Therapy for Inherited Retinal Diseases
Yan, A. L., Du, S. W., & Palczewski, K. (2022) · Vision Research · doi:10.1016/j.visres.2023.108192 · Cited by 40
AAV-PHP.eB transduces both the inner and outer retina with high efficacy in mice
Palfi, A., Chadderton, N., Millington‐Ward, S., Post, I. J. M., Humphries, P., Kenna, P. F., & Farrar, G. J. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.03.016 · Cited by 37
Chambers, C., Soo, G. L., Engel, A. L., Glass, I. A., Frassetto, A., Martini, P. G. V., & Cherry, T. J. (2024) · Translational Vision Science & Technology · doi:10.1167/tvst.13.7.7 · Cited by 38
“32 There are numerous RPE-specific deficiencies, such as TIMP3 in Sorsby fundus dystrophy or BEST1 that causes macular dystrophy that could benefit from gene replacement therapy targeting the RPE, such as the mRNA LNPs in this study.”
BackgroundCarbon Dots Fabrication: Ocular Imaging and Therapeutic Potential
Garner, I., Vichare, R., Paulson, R. J., Appavu, R., Panguluri, S. K., Tzekov, R. T., Şahiner, N., Ayyala, R. S., & Biswal, M. R. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.573407 · Cited by 37
“The greatest challenge for this therapy remains its administration to the posterior eye, presenting increased risks of infection, retinal detachment, and hemorrhage (Peng et al., 2017).”
BackgroundYang, P. G., Birch, D. G., Lauer, A. K., Sisk, R. A., Anand, R., Pennesi, M. E., Iannaccone, A., Yaghy, A., Scaria, A., Jung, J., et al. (2024) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2024.11.021 · Cited by 39
Voretigene Neparvovec: An Emerging Gene Therapy for the Treatment of Inherited Blindness
Patel, U. A., Boucher, M., de Léséleuc, L., & Visintini, S. M. (2016) · Europe PMC (PubMed Central) · Cited by 48
Naik, S., Shreya, A. B., Raychaudhuri, R., Pandey, A., Lewis, S. A., Hazarika, M., Bhandary, S. V., Rao, B. S. S., & Mutalik, S. (2021) · Life Sciences · doi:10.1016/j.lfs.2020.118712 · Cited by 33
Next generation therapeutics for retinal neurodegenerative diseases
Appell, M. B., Pejavar, J., Pasupathy, A., Rompicharla, S. V. K., Abbasi, S., Malmberg, K., Kolodziejski, P., & Ensign, L. M. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.01.063 · Cited by 34
Recent Advances in Nanomedicine for Ocular Fundus Neovascularization Disease Management
Zhou, Y., Xu, M., Shen, W., Xu, Y., Shao, A., Xu, P., Yao, K., Han, H., & Ye, J. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202304626 · Cited by 44
Self-citationCRISPR-dependent base editing as a therapeutic strategy for rare monogenic disorders
Cabré-Romans, J.-J., & Cuella-Martin, R. (2025) · Frontiers in Genome Editing · doi:10.3389/fgeed.2025.1553590 · Cited by 38
“Locally injecting vehicles into the CNS (e.g., via intrathecal injection) or eye (e.g., via subretinal injection) can circumvent biological barriers and enable access to certain important cell populations (Bottros and Christo, 2014; Peng et al., 2017).”
Touchard, E., Benard, R., Bigot, K., Laffitte, J.-D., Buggage, R., Bordet, T., & Behar-Cohen, F. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.07.013 · Cited by 32
A Novel Electromagnetic Driving System for 5-DOF Manipulation in Intraocular Microsurgery
Liu, Y., Song, D., Zhang, G., Bu, Q., Dong, Y., Hu, C., & Shi, C. (2023) · Cyborg and Bionic Systems · doi:10.34133/cbsystems.0083 · Cited by 29
“Consequently, this advancement significantly enhances the accuracy and stability of surgeries [1–3].”
BackgroundBiomechanical considerations for optimising subretinal injections
L’Abbate, D., Prescott, K., Geraghty, B., Kearns, V., & STEEL, D. H. (2024) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2024.05.004 · Cited by 32
Injection pressure levels for creating blebs during subretinal gene therapy
Scruggs, B. A., Vasconcelos, H. M., Matioli da Palma, M., Kogachi, K., Pennesi, M. E., Yang, P., Bailey, S. T., & Lauer, A. K. (2022) · Gene Therapy · doi:10.1038/s41434-021-00294-2 · Cited by 28
Regulation of the Ocular Cell/Tissue Response by Implantable Biomaterials and Drug Delivery Systems
Baino, F., & Kargozar, S. (2020) · Bioengineering · doi:10.3390/bioengineering7030065 · Cited by 29
“, gene therapy, cell therapy) to treat vitreoretinal diseases [35].”
BackgroundRecent advances in slow and sustained drug release for retina drug delivery
Béhar‐Cohen, F. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1618829 · Cited by 28
“of viral vectors for gene therapy [53,54] or to the injection of”
BackgroundBeyond the injection: delivery systems reshaping retinal disease management
Rowe, L. W., Akotoye, C., Harris, A., & Ciulla, T. A. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2496424 · Cited by 26
“Thus, alternative pathways involving suprachoroi-dal and intravitreal administration are also being investigated to avoid such complications evident with PPV [81].”
Chen, K.-S., Chan, H.-C., & Chan, C.-M. (2025) · Drugs · doi:10.1007/s40265-025-02237-2 · Cited by 27
“However, subretinal injection offers more direct targeting of affected cells compared with intravit-real injection, making it the preferred method for many retinal gene therapies [85].”
Robot-assisted subretinal injection system: development and preliminary verification
Yang, K., Jin, X., Wang, Z., Fang, Y., Zhao, L., Yang, Z., Cong, J., Yang, Y., Huang, Y., & Wang, L. (2022) · BMC Ophthalmology · doi:10.1186/s12886-022-02720-4 · Cited by 25
“Introduction As a novel intraocular drug delivery method that can act directly on retinal tissues, subretinal injection has been increasingly used in scientific research and clinical practice in ophthalmology, especially for submacular hemorrhage (SMH), gene and stem cell therapy [1, 2].”
BackgroundViral-vector-delivered anti-angiogenic therapies to the eye
Koponen, S., Kokki, E., Kinnunen, K., & Ylä-Herttuala, S. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13020219 · Cited by 24
“In preclinical trials, the subretinal injections are delivered by the transcorneal route through the pupil passing the lens and retina, by the trans-scleral route through the vitreous, and by the trans-scleral route through the choroid and Bruch’s membrane [28].”
BackgroundCRISPR-Based Genome Editing as a New Therapeutic Tool in Retinal Diseases
Rasoulinejad, S. A., & Maroufi, F. (2021) · Molecular Biotechnology · doi:10.1007/s12033-021-00345-4 · Cited by 26
X-Linked Retinitis Pigmentosa Gene Therapy: Preclinical Aspects
Mansouri, V. (2022) · Ophthalmology and Therapy · doi:10.1007/s40123-022-00602-y · Cited by 25
“Common methods currently used to inject viral vectors into the eye include subretinal and intravitreal injections [116].”
BackgroundMethodInfluentialSteady-Hand Eye Robot 3.0: Optimization and Benchtop Evaluation for Subretinal Injection
Alamdar, A., Usevitch, D. E., Wu, J., Taylor, R. H., Gehlbach, P. L., & Iordachita, I. I. (2023) · IEEE Transactions on Medical Robotics and Bionics · doi:10.1109/tmrb.2023.3336975 · Cited by 28
“Delivery risks include irreversible damage to the retina and ineffective delivery of the cell therapy [15], [16], [17], [18], [19], among others.”
BackgroundPoh, S. S. J., Sia, J. T., Yip, M. Y. T., Tsai, A. S. H., Lee, S. Y., Tan, G. S. W., Weng, C. Y., Kadonosono, K., Kim, M., Yonekawa, Y., et al. (2024) · Ophthalmology Retina · doi:10.1016/j.oret.2024.01.018 · Cited by 23
Cell Therapy for Retinal Degenerative Diseases: Progress and Prospects
Wu, K. Y., Dhaliwal, J. K., Sasitharan, A., & Kalevar, A. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16101299 · Cited by 25
“While subretinal injections enable direct effects on cells and tissue in the subretinal space, there can be complications such as retinal detachment [99].”
BackgroundCell-Based Therapies for Age-Related Macular Degeneration
Khateb, S., Jha, S., Bharti, K., & Banin, E. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-66014-7_11 · Cited by 24
Controlled Subretinal Injection Pressure Prevents Damage in Pigs
Olufsen, M. E., Spindler, L., Sørensen, N. B., Christiansen, A. T., Alberti, M., Heegaard, S., & Kiilgaard, J. F. (2022) · Ophthalmologica · doi:10.1159/000522110 · Cited by 22
Dosmar, E., Vuotto, G., Su, X., Roberts, E., Lannoy, A., Bailey, G. J., Mieler, W. F., & Kang‐Mieler, J. J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13111862 · Cited by 23
“Subretinal injection is considered a more recent and novel approach to ocular drug delivery, has been shown to provide a safe approach to injectable gene therapies [14], and is particularly useful for providing a minimally invasive yet direct route to a very precise location [15].”
BackgroundHints for gentle submacular injection in non-human primates based on intraoperative OCT guidance
Tan, G. S. W., Liu, Z., Ilmarinen, T., Barathi, V. A., Chee, C. K., Lingam, G., Su, X., & Stanzel, B. V. (2021) · Translational Vision Science & Technology · doi:10.1167/tvst.10.1.10 · Cited by 21
CRISPR Technology for Ocular Angiogenesis
Chung, S. H., Sin, T.-N., Ngo, T., & Yiu, G. C. (2020) · Frontiers in Genome Editing · doi:10.3389/fgeed.2020.594984 · Cited by 21
“, 2009) and exhibits minimal immunogenicity due to retinal immune privilege (Peng et al., 2017).”
BackgroundLee, S., & Kang, J. U. (2021) · Journal of Biomedical Optics · doi:10.1117/1.jbo.26.6.068001 · Cited by 25
Novel Approaches in the Drug Development and Delivery Systems for Age-Related Macular Degeneration
Paliwal, H., Prajapati, B. G., Srichana, T., Singh, S. K., & Patel, R. J. (2023) · Life · doi:10.3390/life13020568 · Cited by 22
Seeing the Future: A Review of Ocular Therapy
Whalen, M., Akula, M., McNamee, S. M., DeAngelis, M. M., & Haider, N. B. (2024) · Bioengineering · doi:10.3390/bioengineering11020179 · Cited by 21
“The major barrier to subretinal delivery is the blood–retinal barrier, formed by the retinal vasculature, which limits the types of therapies that can be delivered using this approach to those that can be taken up by retinal or vascular endothelial cells, such as gene and antibody therapies [115].”
BackgroundHan, J., Chang, H., Yang, J., Choi, H., Park, H., Jun, H., Choi, J., Paik, S.-S., Chung, K., Shin, H., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512068 · Cited by 20
“A subretinal injection is widely used in scientific research and clinical applications and is regarded as one of the best strategies for gene therapy or stem cell transplantation [41,42].”
BackgroundMagnetically Assisted Drug Delivery of Topical Eye Drops Maintains Retinal Function In Vivo in Mice
Bassetto, M., Ajoy, D., Poulhès, F., Obringer, C., Walter, A., Messadeq, N., Sadeghi, A., Puranen, J., Ruponen, M., Kettunen, M. I., et al. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13101650 · Cited by 20
Exploring Stem-Cell-Based Therapies for Retinal Regeneration
Radu, M., Brănişteanu, D. C., Pîrvulescu, R. A., Dumitrescu, O.-M., Ionescu, M. A., & Zemba, M. (2024) · Life · doi:10.3390/life14060668 · Cited by 22
“The successful application of human embryonic stem cell-derived RPE in the subretinal space attests to its relative safety when executed with precision [73].”
BackgroundOCT imaging of rod mitochondrial respiration in vivo
Berkowitz, B. A., & Qian, H. (2021) · Experimental Biology and Medicine · doi:10.1177/15353702211013799 · Cited by 21
“In turn, this acidified IPM upregulates water efflux co-transporters in the RPE.”
BackgroundInfluentialCRISPR delivery systems for organ-specific targeting: Advances and challenges
Du, J., Wu, Q., Liu, C., Wang, N., & Gong, C. (2025) · Precision medicine and engineering. · doi:10.1016/j.preme.2025.100048 · Cited by 21
Gene and cell therapy for age-related macular degeneration: A review
Trincão-Marques, J., Ayton, L. N., Hickey, D. G., Marques‐Neves, C., Guymer, R. H., Edwards, T. L., & Sousa, D. C. (2024) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2024.05.002 · Cited by 25
Subretinal injection in mice to study retinal physiology and disease
Huang, P., Narendran, S., Pereira, F., Fukuda, S., Nagasaka, Y., Apicella, I., Yerramothu, P., Marion, K. M., Cai, X. T., Sadda, S. R., et al. (2022) · Nature Protocols · doi:10.1038/s41596-022-00689-4 · Cited by 19
Choi, S. W., Seo, S., Hong, H. K., Yoon, S. J., Kim, M., Moon, S., Lee, J. Y., Lim, J., Lee, J. B., & Woo, S. J. (2023) · Tissue Engineering and Regenerative Medicine · doi:10.1007/s13770-023-00555-8 · Cited by 18
“In addition, sub-retinal injection generally requires surgical procedures that can lead to various surgery-related complications, such as cataracts, retinal detachment, submacular hemorrhage, and macular hole [35, 36].”
BackgroundRetina transduction by rAAV2 after intravitreal injection: Comparison between mouse and rat
Dias, M. S., Araujo, V. G., Vasconcelos, T., Li, Q., Hauswirth, W. W., Linden, R., & Petrs-Silva, H. (2019) · Gene Therapy · doi:10.1038/s41434-019-0100-9 · Cited by 17
Hadady, H., Karamali, F., Ejeian, F., Soroushzadeh, S., & Nasr‐Esfahani, M. H. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04375-2 · Cited by 17
A Comparative Analysis of Models for AAV-Mediated Gene Therapy for Inherited Retinal Diseases
Alsalloum, A., Gornostal, E. A., Mingaleva, N., Pavlov, R. E., Kuznetsova, E., Antonova, E., Nadzhafova, A., Колотова, Д. Е., Кадышев, В. В., Mityaeva, O. N., et al. (2024) · Cells · doi:10.3390/cells13201706 · Cited by 20
“Additionally, subretinal injection may facilitate the potential for repeat transduction utilizing AAV particles, owing to the absorption characteristics of the vector suspension into the extracellular matrix of the outer retinal layers [62,70].”
BackgroundNew Method for Efficient siRNA Delivery in Retina Explants: Reverse Magnetofection
Bassetto, M., Sen, M., Poulhès, F., Arango‐González, B., Bonvin, E., Sapet, C., Ueffing, M., & Zelphati, O. (2021) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.1c00132 · Cited by 18
Ross, M., Obolensky, A., Averbukh, E., Ezra-Elia, R., Yamin, E., Honig, H., Dvir, H., Rosov, A., Hauswirth, W. W., Gootwine, E., et al. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.023 · Cited by 16
“12 Second, most subretinally injected vectors will only transduce cells that are within the area of the subretinal bleb formed during surgery, thus limiting the effect of the treatment to specific areas of the retina.”
Covello, G., Ibrahim, G. H., Bacchi, N., Casarosa, S., & Denti, M. A. (2022) · Nucleic Acid Therapeutics · doi:10.1089/nat.2021.0053 · Cited by 18
MacLaren, R. E., Audo, I., Fischer, M. D., Huckfeldt, R. M., Lam, B. L., Pennesi, M. E., Sisk, R., Gow, J. A., Li, J., Zhu, K., et al. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.017 · Cited by 15
“47,48 Prior exposure to tim-repigene emparvovec did not increase the serious TEAE risk upon second surgery, potentially associated with a lower complication risk given surgeons ’ greater procedural familiarity.”
Retinal Degeneration: Molecular Mechanisms and Therapeutic Strategies
Wu, X., Yan, N., & Zhang, M. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666211129122908 · Cited by 16
Retinal Degeneration Caused by Ago2 Disruption
Chen, X., Zhang, C.-J., Wang, Y.-H., & Jin, Z. (2021) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.62.12.14 · Cited by 15
van der Veen, I., Heredero Berzal, A., Koster, C., ten Asbroek, A. L. M. A., Bergen, A. A., & Boon, C. J. F. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021267 · Cited by 14
“Post-developmental adult vector delivery at 13 weeks was able to restore RS1 expression and rescue the ERG waveform and improve the scotopic b-wave by 6 months of age, but it did not lead to any improvements in retinal morphology or photoreceptor survival [71].”
BackgroundRetinal gene therapy using epiretinal AAV-containing fibrin hydrogel implants
Scruggs, B. A., Berger, A., Knudsen, T., Kopp, F. N., Hill, M., Trncic, E., Anderson, K., Iezzi, R., & Marmorstein, A. D. (2025) · Science Advances · doi:10.1126/sciadv.adv7922 · Cited by 13
“Furthermore, elevated injection pressures may increase flow-related complications, such as over-stretching or thinning of the retina, secondary macular hole, or excessive egress of the vector solution ( 31 ).”
Abid, A., Duval, R., & Boutopoulos, C. (2022) · Biomedical Optics Express · doi:10.1364/boe.448471 · Cited by 15
Bone marrow-derived mononuclear stem cells in the treatment of retinal degenerations
García‐Ayuso, D., Pierdomenico, J. D., García‐Bernal, D., Vidal‐Sanz, M., & Villegas-Pérez, M. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.335692 · Cited by 12
“…thus to photoreceptors, has been described to possess a more direct therapeutic effects on the subretinal space, 1940 |NEURAL REGENERATION RESEARCH|Vol 17|No. 9|September 2022 being therefore considered as a suitable therapeutic alternative for external vitreoretinal disorders (Peng et al., 2017).”
BackgroundPars Plana Vitrectomy in Inherited Retinal Diseases: A Comprehensive Review of the Literature
Iovino, C., Rosolia, A., Damiano, L., Iodice, C. M., Iorio, V. D., Testa, F., & Simonelli, F. (2023) · Life · doi:10.3390/life13061241 · Cited by 12
“The use of dyes, the light toxicity, and the risk of scar development have always discouraged the execution of vitreoretinal surgery in eyes with IRDs [8,86–90].”
BackgroundMethodInfluentialFast OCT-Based Needle Tracking for Retinal Microsurgery Using Dynamic Spiral Scanning
Xu, P., Ourak, M., Borghesan, G., & Poorten, E. V. (2024) · IEEE Transactions on Medical Robotics and Bionics · doi:10.1109/tmrb.2024.3464693 · Cited by 11
Intractable Ocular Diseases and Treatment Progress
Zhang, X., Li, S., Tang, Y., Guo, Y., & Gao, S. (2020) · AAPS PharmSciTech · doi:10.1208/s12249-020-01774-1 · Cited by 12
Huang, Y., Pang, S., Li, L., Do, C. W., Luo, Q., 郑宗立, & Xiong, W. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114499 · Cited by 12
Chiang, M.-C., & Chern, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052529 · Cited by 10
Metadata
- Authors
- Peng, Y., Tang, L., & Zhou, Y.
- Affiliations
- Central South University (CN)
- Venue
- Ophthalmic Research
- Publisher
- S. Karger AG
- Published
- 2017
- Volume
- 58
- Issue
- 4
- Pages
- 217-226
- ISSN
- 0030-3747 (ISSN-L)
- 1423-0259
- OpenAlex
- W2752393253
- Cited by
- 175
- References
- 108
- Citations by year
- 2026: 13 · 2025: 25 · 2024: 27 · 2023: 21 · 2022: 29 · 2021: 24 · 2020: 15 · 2019: 14 · 2018: 6
- FWCI
- 3.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Ophthalmic Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Keywords
- subretinal injection, ocular drug delivery, vitreoretinal disease, gene therapy, cell therapy, stem cell therapy, retinitis pigmentosa, age-related macular degeneration, Leber congenital amaurosis, degenerative retinal diseases, injection complications
- MeSH terms
- Animals, Genetic Vectors, Humans, Injections, Retina, Retinal Diseases, Genetic Therapy, Drug Delivery Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.